Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:ALV NYSE:CS NASDAQ:TLX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALVAutoliv$117.38-1.3%$121.32$99.16▼$132.17$8.91B1.35646,452 shs733,165 shsCSCredit Suisse Group$0.89+1.0%$0.89$0.82▼$6.36$2.76B1.2737.84 million shs63.95 million shsTLXTelix Pharmaceuticals$11.55-1.6%$10.31$6.28▼$16.98$3.98B-0.31203,572 shs206,869 shs7 Stocks to Buy Before the Robotics RevolutionRobotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming to the United States, and there are four ways that investors can gain exposure to this new robotics revolution. Plus, learn which seven companies are most positioned to benefit as intelligent robots enter the workforce. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALVAutoliv-1.43%+3.53%-8.57%+6.81%+1.51%CSCredit Suisse Group0.00%0.00%-0.47%-0.47%-0.47%TLXTelix Pharmaceuticals-1.62%-2.45%+25.27%+17.86%-26.39%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALVAutoliv$117.38-1.3%$121.32$99.16▼$132.17$8.91B1.35646,452 shs733,165 shsCSCredit Suisse Group$0.89+1.0%$0.89$0.82▼$6.36$2.76B1.2737.84 million shs63.95 million shsTLXTelix Pharmaceuticals$11.55-1.6%$10.31$6.28▼$16.98$3.98B-0.31203,572 shs206,869 shs7 Stocks to Buy Before the Robotics RevolutionRobotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming to the United States, and there are four ways that investors can gain exposure to this new robotics revolution. Plus, learn which seven companies are most positioned to benefit as intelligent robots enter the workforce. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALVAutoliv-1.43%+3.53%-8.57%+6.81%+1.51%CSCredit Suisse Group0.00%0.00%-0.47%-0.47%-0.47%TLXTelix Pharmaceuticals-1.62%-2.45%+25.27%+17.86%-26.39%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALVAutoliv 2.62Moderate Buy$135.2715.24% UpsideCSCredit Suisse Group 0.00N/AN/AN/ATLXTelix Pharmaceuticals 2.75Moderate Buy$21.0081.82% UpsideCurrent Analyst Ratings BreakdownLatest TLX, ALV, CS, and MUV2 Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/7/2026TLXTelix Pharmaceuticals CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$22.50 ➝ $22.007/7/2026TLXTelix Pharmaceuticals HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$20.007/6/2026ALVAutoliv Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeBuy (B-) ➝ Buy (B)7/6/2026TLXTelix Pharmaceuticals WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$22.006/25/2026ALVAutoliv Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetEqual Weight$116.00 ➝ $122.006/15/2026ALVAutoliv Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold (C+) ➝ Buy (B-)6/15/2026ALVAutoliv UBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetNeutral$110.00 ➝ $122.006/15/2026ALVAutoliv Jefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold5/6/2026ALVAutoliv Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy (B-) ➝ Hold (C+)4/21/2026ALVAutoliv Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold (C+) ➝ Buy (B-)4/20/2026TLXTelix Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D)(Data available from 7/9/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALVAutoliv$10.82B0.81$15.13 per share7.76$33.99 per share3.45CSCredit Suisse Group$13.76B0.20$0.25 per share3.51$15.26 per share0.06TLXTelix Pharmaceuticals$803.79M4.88$0.04 per share278.44$1.23 per share9.39Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALVAutoliv$735M$9.3012.629.820.806.45%29.03%8.75%7/17/2026 (Estimated)CSCredit Suisse Group-$7.64B$0.651.36N/AN/A15.12%23.83%1.81%N/ATLXTelix Pharmaceuticals-$7.12MN/AN/A105.00N/AN/AN/AN/A8/20/2026 (Estimated)Latest TLX, ALV, CS, and MUV2 EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails7/17/2026Q2 2026ALVAutoliv$2.42N/AN/AN/A$2.77 billionN/A4/18/2026Q1 2026ALVAutoliv$1.84$2.05+$0.21$1.88$2.61 billion$2.75 billionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthALVAutoliv$3.482.96%+20.27%37.42%1 YearsCSCredit Suisse Group$0.044.52%-49.51%6.15%N/ATLXTelix PharmaceuticalsN/AN/AN/AN/AN/ALatest TLX, ALV, CS, and MUV2 DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date5/6/2026ALVAutolivquarterly$0.872.95%5/20/20265/20/20266/8/2026(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALVAutoliv0.641.080.82CSCredit Suisse Group2.791.531.53TLXTelix Pharmaceuticals1.081.431.27Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALVAutoliv69.57%CSCredit Suisse Group11.20%TLXTelix PharmaceuticalsN/AInsider OwnershipCompanyInsider OwnershipALVAutoliv0.34%CSCredit Suisse GroupN/ATLXTelix PharmaceuticalsN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALVAutoliv64,30074.86 million74.61 millionOptionableCSCredit Suisse Group50,4803.11 billionN/ANo DataTLXTelix Pharmaceuticals1,184339.38 millionN/AN/ATLX, ALV, CS, and MUV2 HeadlinesRecent News About These CompaniesTelix Pharmaceuticals (NASDAQ:TLX) Receives Outperform Rating from WedbushJuly 7 at 10:33 AM | americanbankingnews.comHC Wainwright Reaffirms "Buy" Rating for Telix Pharmaceuticals (NASDAQ:TLX)July 7 at 8:36 AM | americanbankingnews.comFDA Alignment to Advance ProstACT Global Phase 3 TrialJuly 1, 2026 | globenewswire.comTelix Pharmaceuticals Limited (TLX) Discusses Neurologic Oncology Portfolio and Advances in Therapeutic and Diagnostic Agents - SlideshowJuly 1, 2026 | seekingalpha.comTelix Pharmaceuticals Limited (TLX) Discusses Neurologic Oncology Portfolio and Advances in Therapeutic and Diagnostic Agents TranscriptJune 30, 2026 | seekingalpha.comChartWatch ASX scans: Pro Medicus, Life360, Telix Pharmaceuticals, Zip Co, Global X Cybersecurity ETF, Lindian ResourcesJune 29, 2026 | msn.comTelix hosts webinar on theranostics for glioma and glioblastomaJune 23, 2026 | msn.comTelix Educational Webinar: Neuro-Oncology Portfolio Update and Physician Perspectives on Future Therapeutic DirectionsJune 22, 2026 | globenewswire.comTelix Pharmaceuticals (TLX), United Imaging Healthcare Form Strategic Theranostics Research PartnershipJune 17, 2026 | insidermonkey.comPrediction: I think Telix shares could double in value in 2026. Here's whyJune 11, 2026 | fool.com.auTelix Pharmaceuticals Limited (TLX) Presents at 46th Annual William Blair Growth Stock Conference - SlideshowJune 3, 2026 | seekingalpha.comTelix and United Imaging Announce Strategic Theranostics CollaborationJune 2, 2026 | globenewswire.comProstACT Global Phase 3 (Part 1) Data Presented in Late-Breaking Oral Session at ASCO 2026June 1, 2026 | globenewswire.comIs Telix (ASX:TLX) Quietly Assembling a Connected Oncology Platform That Reshapes Its Moat?May 29, 2026 | finance.yahoo.comTelix to Participate in William Blair Growth Stock and Jefferies Global Healthcare ConferencesMay 27, 2026 | globenewswire.comTelix Pharmaceuticals: PSMA Radiopharmaceutical Player Is Revving UpMay 18, 2026 | seekingalpha.comIPAX-2 Study of TLX101-Tx in First-line Glioblastoma Completes Enrolment and Confirms DosingMay 18, 2026 | globenewswire.comTelix Pharmaceuticals Ltd ADR TLXMay 17, 2026 | morningstar.comMTelix Announces Collaborations to Explore PSMA-PET Imaging in Emerging Prostate Cancer Treatment ApproachesMay 15, 2026 | globenewswire.comTelix Issues New Shares to Complete Deferred ImaginAb Acquisition PaymentMay 10, 2026 | theglobeandmail.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All Headlines3 Stocks to Watch If the Strait of Hormuz ReopensBy Chris Markoch | June 17, 2026Cheap Thrills: Why These 3 Entertainment Stocks Are SoaringBy Dan Schmidt | June 17, 2026The AI Boom Has a Second Act—And It's Playing Out in OpticsBy Bridget Bennett | June 29, 20262 AI Stocks That Could Benefit as AI Moves Beyond the Data CenterBy Thomas Hughes | July 5, 20263 Penny Stocks Under $5 Backed by Real Revenue GrowthBy Chris Markoch | June 20, 2026TLX, ALV, CS, and MUV2 Company DescriptionsAutoliv NYSE:ALV$117.38 -1.58 (-1.33%) Closing price 07/8/2026 03:59 PM EasternExtended Trading$117.31 -0.07 (-0.06%) As of 05:54 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Autoliv, Inc., through its subsidiaries, develops, manufactures, and supplies passive safety systems to the automotive industry in Europe, the Americas, China, Japan, and rest of Asia. It offers passive safety systems, including modules and components for frontal-impact airbag protection systems, side-impact airbag protection systems, seatbelts, steering wheels, and inflator technologies. The company also provides mobility safety solutions, such as pedestrian protection, battery cut-off switches, connected safety services, and safety solutions for riders of powered two wheelers. It primarily serves car manufacturers. Autoliv, Inc. was founded in 1953 and is headquartered in Stockholm, Sweden.Credit Suisse Group NYSE:CSCredit Suisse Group AG is a holding company, which engages in the provision of financial services. It operates through the following four divisions: Wealth Management, Investment Bank, Swiss Bank and Asset Management and four geographic regions: Switzerland, Europe, the Middle East and Africa (EMEA), Asia Pacific, and Americas. The Wealth Management division offers comprehensive wealth management and investment solutions, tailored financing, and advisory services to ultra-high-net-worth (UHNW) and high net-worth (HNW) individuals and external asset managers. The Investment Bank division offers a broad range of financial products and services focused on client-driven businesses and also supports Credit Suisse's Wealth Management division and its clients. The Swiss Bank division offers comprehensive advice and a wide range of financial solutions to private, corporate, and institutional clients in Switzerland. The Asset Management division offers investment solutions and services globally to a broad range of clients, including pension funds, governments, foundations and endowments, corporations, and individuals. The company was founded by Alfred Escher on July 5, 1856 and is headquaTelix Pharmaceuticals NASDAQ:TLX$11.55 -0.19 (-1.62%) Closing price 07/8/2026 04:00 PM EasternExtended Trading$11.48 -0.07 (-0.56%) As of 04:01 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Telix Pharmaceuticals Limited. engages in the development and commercialization of several clinical-stage oncology assets. It operates through the following segments: Commercial, Product Development, and Group and Unallocated. The Commercial segment includes sales of Illuccix and other products subsequent to obtaining regulatory approvals. The Product Development segment develops radiopharmaceutical products for commercialization. It focuses on cancer care, specifically in prostate, renal or kidney and glioblastoma or brain cancer. Its products include TLX250, TLX591, and TLX101. The company was founded by Andreas Kluge and Christian P. Behrenbruch in November 2015 and is headquartered in Melbourne, Australia. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Why Exxon Could Be the Market's Next Big Comeback Stock Why Penguin Solutions May Be the Smartest AI Infrastructure Stock The Market Just Got Shaken—These 3 ETFs May Come Out Stronger Meta Platforms’ Cloud Push: Growth Opportunity Versus AI Concerns A Market Panic Just Discounted the AI Highway's Tollbooth Vertex’s Crinetics Deal Balances Growth with Integration Risk Apple and Broadcom Forge a Decade-Long Silicon Fortress These 3 Cash-Flow Stocks Give Investors More Than Just Growth Potential Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
